Life sciences news
-
SwiftPharma launches ODIN.AI: A groundbreaking AI-augmented antibody discovery platform
Monday October 9th 2023
Read more
-
Agomab receives FDA Fast Track Designation for AGMB-129 in Fibrostenosing Crohn’s Disease and starts STENOVA Phase 2a clinical trial
Friday October 6th 2023
Read more
-
Rejuvenate Biomed announces positive results from Phase 1b clinical trial with RJx-01 in sarcopenia
Wednesday October 4th 2023
Read more
-
SwiftPharma and Medace sign strategic collaboration agreement for biomanufacturing and purification of promising medicinal proteins.
Wednesday September 27th 2023
Read more
-
Mithra Announces Presentation of Positive Data on Estetrol (E4) Native Estrogen
Wednesday September 27th 2023
Read more
-
argenx announces positive CHMP opinion for subcutaneous efgartigimod for generalized myasthenia gravis
Friday September 15th 2023
Read more
-
SwiftPharma and the Population Council Pursue Agreement to Manufacture Griffithsin Needed for the Development of a Fast-Dissolving Insert for Protection Against HIV
Friday September 8th 2023
Read more
-
SwiftPharma and AntoXa Corporation sign exclusive collaboration agreement to support the development and commercialization of a plant-made antibody against ricin exposure
Friday September 1st 2023
Read more
-
Become a flanders.bio member
Your news here?
-
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
Tuesday August 29th 2023
Read more
-
ViroVet achieves groundbreaking results with antiviral drug against BVD
Monday August 28th 2023
Read more
-
argenx reports positive topline data from ADHERE study of VYVGART Hytrulo in patients with chronic inflammatory demyelinating polyneuropathy
Monday July 17th 2023
Read more
More info?
Contact us
Ellen Telleir
Communication Coordinator
